Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

• Timothy Fitzgerald,
• Maryia Zhdanava,
• Dominic Pilon,
• Aditi Shah,
• Patrick Lefebvre,
• Steven R. Feldman

Affiliations

Timothy Fitzgerald

Janssen Scientific Affairs, LLC

Maryia Zhdanava

Groupe d’analyse

Dominic Pilon

Groupe d’analyse

Aditi Shah

Groupe d’analyse

Patrick Lefebvre

Groupe d’analyse

Steven R. Feldman

Wake Forest University School of Medicine